MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6476-6505

  Cekaite, Lina ^a   Eide, Peter W ^a   Lind, Guro E ^a   Skotheim, Rolf I ^a   Lothe, Ragnhild A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biomarker; Colorectal neoplasm; Metastasis; miRNA; Target gene

Indexed keywords

MICRORNA; MICRORNA 126; MICRORNA 135A; MICRORNA 135B; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 181B; MICRORNA 183; MICRORNA 18A; MICRORNA 19; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 20A; MICRORNA 21; MICRORNA 25; MICRORNA 26A; MICRORNA 26B; MICRORNA 31; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 429; MICRORNA 4689; MICRORNA 520A; MICRORNA 525A; MICRORNA LET 7I; SARACATINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

3' UNTRANSLATED REGION; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CCND1 GENE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CTNNG1 GENE; DOWN REGULATION; DRUG EFFICACY; DRUG RESISTANCE; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; ERK GENE; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; HUMAN; KLF5 GENE; LEF1 GENE; METASTATIC COLORECTAL CANCER; NKRAS GENE; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ANIMAL; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS;

EID: 84988272333     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6390     Document Type: Article

References (305)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J. W., Comber H., Forman . and Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-1403.
2. Stewart B. W., Wild, C. P. World Cancer Report. 2014.
3. Friedman R. C., Farh K. K., Burge C. B. and Bartel D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19(1):92-105.
4. Kozomara A. and Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research. 2014; 42(D1):D68-D73.
5. Mestdagh P., Hartmann N., Baeriswyl L., Andreasen D., Bernard N., Chen C., Cheo D., D'andrade P., Demayo M., Dennis L., Derveaux S., Feng Y., Fulmer-Smentek S., et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 11(8):809-815.
6. Brennecke J., Hipfner D. R., Stark A., Russell R. B. and Cohen S. M. bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in Drosophila. Cell. 2003; 113(1):25-36.
7. Chen Ch., Li L., Lodish H. F. and Bartel D. P. MicroRNAs Modulate Hematopoietic Lineage Differentiation. Science. 2004; 303(5654):83-86.
8. Lee R. C., Feinbaum R. L. and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-854.
9. Pasquinelli A. E., Reinhart B. J., Slack F., Martindale M. Q., Kuroda M. I., Maller B., Hayward D. C., Ball E. E., Degnan B., Muller P., Spring J., Srinivasan A., Fishman M., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000; 408(6808):86-89.
10. Calin G. A., Dumitru . D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24):15524 - 15529.
11. Michael M. Z., Sm O' Connor, Van Holst Pellekaan N. G., Young G. P. and James R. J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1(12):882-891.
12. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T. and Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-3756.
13. O'donnell K. A., Wentzel E. A., Zeller K. I., Dang C. V. and Mendell J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-843.
14. Ma L., Teruya-Feldstein J. and Weinberg R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-688.
15. Meiri E., Mueller W. C., Rosenwald S., Zepeniuk M., Klinke E., Edmonston T. B., Werner M., Lass U., Barshack I., Feinmesser M., Huszar M., Fogt F., Ashkenazi K., et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012; 17(6):801-812.
16. Clinicaltrials.Gov. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. 2015.
17. Ambros V., Bartel B., Bartel D. P., Burge C. B., Carrington J. C., Chen X., Dreyfuss G., Eddy S. R., Griffiths-Jones S., Marshall M., Matzke M., Ruvkun G. and Tuschl T. A uniform system for microRNA annotation. RNA. 2003; 9(3):277-279.
18. Spizzo R., Nicoloso M. S., Croce C. M. and Calin G. A. SnapShot: MicroRNAs in Cancer. Cell. 2009; 137(3):586.
19. Zeitels L. R., Acharya A., Shi G., Chivukula D., Chivukula R. R., Anandam J. L., Abdelnaby A. A., Balch G. C., Mansour J. C., Yopp A. C., Richardson J. A. and Mendell J. T. Tumor suppression by miR-26 overrides potential oncogenic activity in intestinal tumorigenesis. Genes Dev. 2014; 28(23):2585-2590.
20. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J. and Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2(2):84-89.
21. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H. and Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005; 24(14):2375-2385.
22. Perl A. K., Wilgenbus P., Dahl U., Semb H. and Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392(6672):190-193.
23. Siemens H., Jackstadt R., Hunten S., Kaller M., Menssen A., Gotz U. and Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011; 10(24):4256-4271.
24. Roy S., Levi E., Majumdar A. P. and Sarkar F. H. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012; 5:58-64.
25. Hahn S., Jackstadt R., Siemens H., Hunten S. and Hermeking H. SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J. 2013; 32(23):3079-3095.
26. Rokavec M., Oner M. G., Li H., Jackstadt R., Iang L., Lodygin D., Kaller M., Horst D., Ziegler P. K., Schwitalla S., Slotta-Huspenina J., Bader F. G., Greten F. R., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014; 124(4):1853-1867.
27. Siemens H., Neumann J., Jackstadt R., Mansmann U., Horst D., Kirchner T. and Hermeking H. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013; 19(3):710-720.
28. Gao J., Li N., Dong Y., Li S., Xu L., Li X., Li Y., Li Z., Ng S. S., Sung J. J., Shen L. and Yu J. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene. 2015; 34(31):4142-52.
29. Li X., Zhao H., Zhou X. and Song . Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Mol Med Rep. 2015; 11(1):577-582.
30. Mirna Therapeutics Interim Phase 1 Data http://www.mirnarx.com/ 2015
31. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S. and Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9(6):582-589.
32. Wellner U., Schubert J., Burk U. C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., Zur Hausen A., Brunton V. G., Morton J., Sansom O., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11(12):1487-1495.
33. Chen M. L., Liang L. S. and Wang X. K. miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin Exp Metastasis. 2012; 29(5):457-469.
34. Davalos V., Moutinho C., Villanueva A., Boque R., Silva P., Carneiro F. and Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2012; 31(16):2062-2074.
35. Paterson E. L., Kazenwadel J., Bert A. G., Khew-Goodall Y., Ruszkiewicz A. and Goodall G. J. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013; 15(2):180-191.
36. Hur K., Toiyama Y., Takahashi M., Balaguer F., Nagasaka T., Koike J., Hemmi H., Koi M., Boland C. R. and Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013; 62(9):1315-1326.
37. Sui H., Cai G. X., Pan S. F., Deng W. L., Wang Y. W., Chen Z. S., Cai S. J., Zhu H. R. and Li Q. miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. Mol Cancer Ther. 2014; 13(12):3137-3151.
38. Kahlert C., Klupp F., Brand K., Lasitschka F., Diederichs S., Kirchberg J., Rahbari N., Dutta S., Bork U., Fritzmann J., Reissfelder C., Koch M. and Weitz J. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci. 2011; 102(10):1799-1807.
39. Lu M. H., Huang C. C., Pan M. R., Chen H. H. and Hung W. C. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res. 2012; 18(23):6416-6425.
40. Cekaite L., Rantala J. K., Bruun J., Guriby M., Agesen T. H., Danielsen S. A., Lind G. E., Nesbakken A., Kallioniemi O., Lothe R. A. and Skotheim R. I. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 2012; 14(9):868-879.
41. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
42. Ma F., Song H., Guo B., Zhang Y., Zheng Y., Lin C., Wu Y., Guan G., Sha R., Zhou Q., Wang D., Zhou X., Li J., et al. MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. Oncotarget. 2015; 6(19):17404-17416. doi: 10.18632/oncotarget.3744.
43. Zhang H., Hao Y., Yang J., Zhou Y., Li J., Yin S., Sun C., Ma M., Huang Y. and Xi J. J. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun. 2011; 2:554.
44. Okamoto K., Ishiguro T., Midorikawa Y., Ohata H., Izumiya M., Tsuchiya N., Sato A., Sakai H. and Nakagama H. miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver. EMBO J. 2012; 31(7):1752-1763.
45. Loo J. M., Scherl A., Nguyen A., Man F. Y., Weinberg E., Zeng Z., Saltz L., Paty P. B. and Tavazoie S. F. Extracellular metabolic energetics can promote cancer progression. Cell. 2015; 160(3):393-406.
46. Li Y. and Zhang Z. Potential microRNA-mediated oncogenic intercellular communication revealed by pan-cancer analysis. Sci Rep. 2014; 4:7097.
47. Rosetta Genomics http://www.rosettagenomics.com/ 2015
48. Nosho K., Igarashi H., Nojima M., Ito M., Maruyama R., Yoshii S., Naito T., Sukawa Y., Mikami M., Sumioka W., Yamamoto E., Kurokawa S., Adachi Y., et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014; 35(4):776-783.
49. Wang S., Wang L., Bayaxi N., Li J., Verhaegh W., Janevski A., Varadan V., Ren Y., Merkle D., Meng X., Gao X., Wang H., Ren J., et al. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut. 2013; 62(2):280-289.
50. Weissmann-Brenner A., Kushnir M., Lithwick Yanai G., Aharonov R., Gibori H., Purim O., Kundel Y., Morgenstern S., Halperin M., Niv Y. and Brenner B. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol. 2012; 40(6):2097-2103.
51. Van De Velde C. J., Boelens P. G., Borras J. M., Coebergh J. W., Cervantes A., Blomqvist L., Beets-Tan R. G., Van Den Broek C. B., Brown G., Van Cutsem E., Espin E., Haustermans K., Glimelius B., et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014; 50(1):e1-e34.
52. Zhang J. X., Song W., Chen Z. H., Wei J. H., Liao Y. J., Lei J., Hu M., Chen G. Z., Liao B., Lu J., Zhao H. W., Chen W., He Y. L., et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013; 14(13):1295-1306.
53. Kang W. K., Lee J. K., Oh S. T., Lee S. H. and Jung C. K. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol. 2015; 15(1):2-20.
54. Diaz T., Tejero R., Moreno I., Ferrer G., Cordeiro A., Artells R., Navarro A., Hernandez R., Tapia G. and Monzo M. Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol. 2014; 109(7):676-683.
55. Liu H., Du L., Wen Z., Yang Y., Li J., Wang L., Zhang X., Liu Y., Dong Z., Li W., Zheng G. and Wang C. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis. 2013; 28(5):697-703.
56. Huynh C., Segura M. F., Gaziel-Sovran A., Menendez S., Darvishian F., Chiriboga L., Levin B., Meruelo D., Osman I., Zavadil J., Marcusson E. G. and Hernando E. Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2011; 30(12):1481-1488.
57. Ma Y., Zhang P., Wang F., Zhang H., Yang J., Peng J., Liu W. and Qin H. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012; 61(10):1447-1453.
58. Ma W., Yu J., Qi X., Liang L., Zhang Y., Ding Y., Lin X., Li G. and Ding Y. Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb. Oncotarget. 2015; 6(18):15984-15994. doi: 10.18632/oncotarget.3762.
59. Cappuzzo F., Sacconi A., Landi L., Ludovini V., Biagioni F., D'incecco A., Capodanno A., Salvini J., Corgna E., Cupini S., Barbara C., Fontanini G., Crino L., et al. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer. 2014; 13(1):37-45 e34.
60. Pichler M., Winter E., Ress A. L., Bauernhofer T., Gerger A., Kiesslich T., Lax S., Samonigg H. and Hoefler G. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014; 67(3):198-203.
61. Suto T., Yokobori T., Yajima R., Morita H., Fujii T., Yamaguchi S., Altan B., Tsutsumi S., Asao T. and Kuwano H. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015; 36(3):338-345.
62. Kanaan Z., Rai S. N., Eichenberger M. R., Roberts H., Keskey B., Pan J. and Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256(3):544-551.
63. Monzo M., Martinez-Rodenas F., Moreno I., Navarro A., Santasusagna S., Macias I., Munoz C., Tejero R. and Hernandez R. Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients. Medicine (Baltimore). 2015; 94(1):e145-151.
64. Pu X. X., Huang G. L., Guo H. Q., Guo C. C., Li H., Ye S., Ling S., Jiang L., Tian Y. and Lin T. Y. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25(10):1674-1680.
65. Shan L., Ji Q., Cheng G., Xia J., Liu D., Wu C., Zhu B. and Ding Y. Diagnostic value of circulating miR-21 for colorectal cancer: a meta-analysis. Cancer Biomark. 2015; 15(1):47-56.
66. Ng E. K., Chong W. W., Jin H., Lam E. K., Shin V. Y., Yu J., Poon T. C., Ng S. S. and Sung J. J. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-1381.
67. Wang S., Xiang J., Li Z., Lu S., Hu J., Gao X., Yu L., Wang L., Wang J., Wu Y., Chen Z. and Zhu H. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2013; 136(1):152-161.
68. Yuan D., Li K., Zhu K., Yan R. and Dang C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol Ther. 2015; 16(2):268-275.
69. Perilli L., Vicentini C., Agostini M., Pizzini S., Pizzi M., D'angelo E., Bortoluzzi S., Mandruzzato S., Mammano E., Rugge M., Nitti D., Scarpa A., Fassan M., et al. Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget. 2014; 5(16):6611-6619. doi: 10.18632/oncotarget.2245.
70. Kjersem J. B., Ikdahl T., Lingjaerde O. C., Guren T., Tveit K. M. and Kure E. H. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2014; 8(1):59-67.
71. Koga Y., Yamazaki N., Yamamoto Y., Yamamoto S., Saito N., Kakugawa Y., Otake Y., Matsumoto M. and Matsumura Y. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1844-1852.
72. Koga Y., Yasunaga M., Takahashi A., Kuroda J., Moriya Y., Akasu T., Fujita S., Yamamoto S., Baba H. and Matsumura Y. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila). 2010; 3(11):1435-1442.
73. Zhang J., Fei B., Wang Q., Song M., Yin Y., Zhang B., Ni S., Guo W., Bian Z., Quan C., Liu Z., Wang Y., Yu J., et al. MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget. 2014; 5(23):12083-12096. doi: 10.18632/oncotarget.2499.
74. Inoue A., Yamamoto H., Uemura M., Nishimura J., Hata T., Takemasa I., Ikenaga M., Ikeda M., Murata K., Mizushima T., Doki Y. and Mori M. MicroRNA-29b is a Novel Prognostic Marker in Colorectal Cancer. Ann Surg Oncol. 2014; 12:1-9.
75. Nakano H., Miyazawa T., Kinoshita K., Yamada Y. and Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer. 2010; 127(5):1072-1080.
76. Christensen L. L., Holm A., Rantala J., Kallioniemi O., Rasmussen M. H., Ostenfeld M. S., Dagnaes-Hansen F., Oster B., Schepeler T., Tobiasen H., Thorsen K., Sieber O. M., Gibbs P., et al. Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. PLoS One. 2014; 9(6):e96767.
77. Venkatachalam R., Verwiel E. T., Kamping E. J., Hoenselaar E., Gorgens H., Schackert H. K., Van Krieken J. H., Ligtenberg M. J., Hoogerbrugge N., Van Kessel A. G. and Kuiper R. P. Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer. 2011; 129(7):1635-1642.
78. Rapti S. M., Kontos C. K., Papadopoulos I. N. and Scorilas A. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med. 2014; 52(8):1217-1227.
79. Sarver A. L., French A. J., Borralho P. M., Thayanithy V., Oberg A. L., Silverstein K. A., Morlan B. W., Riska S. M., Boardman L. A., Cunningham J. M., Subramanian S., Wang L., Smyrk T. C., et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009; 9:401.
80. Pizzini S., Bisognin A., Mandruzzato S., Biasiolo M., Facciolli A., Perilli L., Rossi E., Esposito G., Rugge M., Pilati P., Mocellin S., Nitti D., Bortoluzzi S., et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 2013; 14:589.
81. Yang M. H., Yu J., Jiang D. M., Li W. L., Wang S. and Ding Y. Q. microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. J Transl Med. 2014; 12:109.
82. Amodeo V., Bazan V., Fanale D., Insalaco L., Caruso S., Cicero G., Bronte G., Rolfo C., Santini D. and Russo A. Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? Expert Opin Ther Targets. 2013; 17(11):1249-1261.
83. Li L., Sarver A. L., Khatri R., Hajeri P. B., Kamenev I., French A. J., Thibodeau S. N., Steer C. J. and Subramanian S. Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. J Pathol. 2014; 234(4):488-501.
84. Lengauer C., Kinzler K. W. and Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997; 386(6625):623-627.
85. Shibata D., Peinado M. A., Ionov Y., Malkhosyan S. and Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet. 1994; 6(3):273-281.
86. Boland C. R. and Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138(6):2073-2087.
87. Toyota M., Ahuja N., Ohe-Toyota M., Herman J. G., Baylin S. B. and Issa J. P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-8686.
88. Sveen A., Agesen T. H., Nesbakken A., Rognum T. O., Lothe R. A. and Skotheim R. I. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med. 2011; 3(5):32.
89. Lanza G., Ferracin M., Gafa R., Veronese A., Spizzo R., Pichiorri F., Liu C. G., Calin G. A., Croce C. M. and Negrini M. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer. 2007; 6:54.
90. Earle J. S., Luthra R., Romans A., Abraham R., Ensor J., Yao H. and Hamilton S. R. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn. 2010; 12(4):433-440.
91. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., Costinean S., Sandhu S. K., Nuovo G. J., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15):6982-6987.
92. Balaguer F., Moreira L., Lozano J. J., Link A., Ramirez G., Shen Y., Cuatrecasas M., Arnold M., Meltzer S. J., Syngal S., Stoffel E., Jover R., Llor X., et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res. 2011; 17(19):6239-6249.
93. Donehower L. A., Creighton C. J., Schultz N., Shinbrot E., Chang K., Gunaratne P. H., Muzny D., Sander C., Hamilton S. R., Gibbs R. A. and Wheeler D. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol. 2013; 229(1):99-110.
94. Oster B., Linnet L., Christensen L. L., Thorsen K., Ongen H., Dermitzakis E. T., Sandoval J., Moran S., Esteller M., Hansen T. F., Lamy P., Group Colofol Steering, Laurberg S., et al. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer. 2013; 132(10):2303-2315.
95. Svrcek M., El-Murr N., Wanherdrick K., Dumont S., Beaugerie L., Cosnes J., Colombel J. F., Tiret E., Flejou J. F., Lesuffleur T. and Duval A. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis. 2013; 34(4):828-834.
96. Li X., Li X., Liao D., Wang X., Wu Z., Nie J., Bai M., Fu X., Mei Q. and Han . Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1. Curr Protein Pept Sci. 2015; 16(4):301-309.
97. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., Sumani K. M., Alder H., Amadori D., Patel T., Nuovo . J., Fishel R. and Croce C. M. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010; 107(49):21098-21103.
98. El-Murr N., Abidi Z., Wanherdrick K., Svrcek M., Gaub M. P., Flejou J. F., Hamelin R., Duval A. and Lesuffleur T. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer. PLoS One. 2012; 7(2):e31862.
99. Calin G. A., Sevignani C., Dumitru C. D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M. and Croce C. M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004.
100. Diosdado B., Van De Wiel M. A., Terhaar Sive Droste . S., Mongera S., Postma C., Meijerink W. J., Carvalho B. and Meijer G. A. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer. 2009; 101(4):707-714.
101. Guo S. T., Jiang C. C., Wang G. P., Li Y. P., Wang C. Y., Guo X. Y., Yang R. H., Feng Y., Wang F. H., Tseng H. Y., Thorne R. F., Jin L. and Zhang X. D. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 2013; 32(15):1910-1920.
102. Brueckner B., Stresemann C., Kuner R., Mund C., Musch T., Meister M., Sultmann H. and Lyko F. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007; 67(4):1419-1423.
103. Lujambio A., Ropero S., Ballestar E., Fraga M. F., Cerrato C., Setien F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., Spiteri I., Das P. P., Caldas C., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007; 67(4):1424-1429.
104. Grady W. M., Parkin R. K., Mitchell P. S., Lee J. H., Kim Y. H., Tsuchiya K. D., Washington M. K., Paraskeva C., Willson J. K., Kaz A. M., Kroh E. M., Allen A., Fritz B. R., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene. 2008; 27(27):3880-3888.
105. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., Knyazev P., Diebold J. and Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008; 7(16):2591-2600.
106. Ito M., Mitsuhashi K., Igarashi H., Nosho K., Naito T., Yoshii S., Takahashi H., Fujita M., Sukawa Y., Yamamoto E., Takahashi T., Adachi Y., Nojima M., et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int J Cancer. 2014; 135(11):2507-2515.
107. Slattery M. L., Wolff E., Hoffman M. D., Pellatt D. F., Milash B. and Wolff R. K. MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer. 2011; 50(3):196-206.
108. Chivukula R. R., Shi G., Acharya A., Mills E. W., Zeitels L. R., Anandam J. L., Abdelnaby A. A., Balch G. C., Mansour J. C., Yopp A. C., Maitra A. and Mendell J. T. An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell. 2014; 157(5):1104-1116.
109. Hofacker I. L. How microRNAs choose their targets. Nat Genet. 2007; 39(10):1191-1192.
110. Jacobsen A., Silber J., Harinath G., Huse J. T., Schultz N. and Sander C. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol. 2013; 20(11):1325-1332.
111. Clevers H., Loh K. M. and Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014; 346(6205):1248012.
112. Attard T. M., Cuffari C., Tajouri T., Stoner J. A., Eisenberg M. T., Yardley J. H., Abraham S. C., Perry D., Vanderhoof J. and Lynch H. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol. 2004; 99(4):681-686.
113. Miyoshi Y., Nagase H., Ando H., Horii A., Ichii S., Nakatsuru S., Aoki T., Miki Y., Mori T. and Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992; 1(4):229-233.
114. Nagel R., Le Sage C., Diosdado B., Van Der Waal M., Oude Vrielink J. A., Bolijn A., Meijer G. A. and Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008; 68(14):5795-5802.
115. Valeri N., Braconi C., Gasparini P., Murgia C., Lampis A., Paulus-Hock V., Hart J. R., Ueno L., Grivennikov S. I., Lovat F., Paone A., Cascione L., Sumani K. M., et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014; 25(4):469-483.
116. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
117. Kaller M., Liffers S. T., Oeljeklaus S., Kuhlmann K., Roh S., Hoffmann R., Warscheid B. and Hermeking H. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics. 2011; 10(8):M111 010462.
118. Yamada N., Noguchi S., Mori T., Naoe T., Maruo K. and Akao Y. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett. 2013; 335(2):332-342.
119. Drebber U., Lay M., Wedemeyer I., Vallbohmer D., Bollschweiler E., Brabender J., Monig S. P., Holscher A. H., Dienes H. P. and Odenthal M. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successfulneoadjuvant chemoradiotherapy. Int J Oncol. 2011; 39(2):409-415.
120. Pichler M., Winter E., Stotz M., Eberhard K., Samonigg H., Lax S. and Hoefler G. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer. 2012; 106(11):1826-1832.
121. Zhang J., Zhang K., Bi M., Jiao X., Zhang D. and Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2014; 25(3):346-352.
122. Schepeler T., Holm A., Halvey P., Nordentoft I., Lamy P., Riising E. M., Christensen L. L., Thorsen K., Liebler D. C., Helin K., Orntoft T. F. and Andersen C. L. Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene. 2012; 31(22):2750-2760.
123. Lan F., Yue X., Han L., Shi Z., Yang Y., Pu P., Yao Z. and Kang C. Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer. Int J Oncol. 2012; 40(2):519-526.
124. Kim N. H., Cha Y. H., Kang S. E., Lee Y., Lee I., Cha S. Y., Ryu J. K., Na J. M., Park C., Yoon H. G., Park G. J., Yook J. I. and Kim H. S. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013; 12(10):1578-1587.
125. Kim N. H., Kim H. S., Kim N. G., Lee I., Choi H. S., Li X. Y., Kang S. E., Cha S. Y., Ryu J. K., Na J. M., Park C., Kim K., Lee S., et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 2011; 4(197):ra71.
126. Takahashi M., Sung B., Shen Y., Hur K., Link A., Boland C. R., Aggarwal B. B. and Goel A. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 2012; 33(12):2441-2449.
127. Dews M., Fox J. L., Hultine S., Sundaram P., Wang W., Liu Y. Y., Furth E., Enders G. H., El-Deiry W., Schelter J. M., Cleary M. A. and Thomas-Tikhonenko A. The myc-miR-17~92 axis blunts TGF(beta) signaling and production of multiple TGF(beta)-dependent antiangiogenic factors. Cancer Res. 2010; 70(20):8233-8246.
128. Oda K., Matsuoka Y., Funahashi A. and Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005; 1:1-17.
129. Brink M., De Goeij A. F., Weijenberg M. P., Roemen G. M., Lentjes M. H., Pachen M. M., Smits K. M., De Bruine A. P., Goldbohm R. A. and Van Den Brandt P. A. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003; 24(4):703-710.
130. Saltz L. B., Meropol N. J., Loehrer P. J., Sr., Needle M. N., Kopit J. and Mayer R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7):1201-1208.
131. Dienstmann R., Salazar R. and Tabernero J. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2015; 35:e149-156.
132. Johnson S. M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K. L., Brown D. and Slack F. J. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-647.
133. Smits K. M., Paranjape T., Nallur S., Wouters . A., Weijenberg M. P., Schouten L. J., Van Den Brandt P. A., Bosman F. T., Weidhaas J. B. and Van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011; 17(24):7723-7731.
134. Ryan B. M., Robles A. I. and Harris C. C. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter. Clin Cancer Res. 2012; 18(12):3487-3488.
135. Graziano F., Canestrari E., Loupakis F., Ruzzo A., Galluccio N., Santini D., Rocchi M., Vincenzi B., Salvatore L., Cremolini C., Spoto C., Catalano V., D'emidio S., et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 2010; 10(5):458-464.
136. Sha D., Lee A. M., Shi Q., Alberts . R., Sargent D. J., Sinicrope F. A. and Diasio R. B. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014; 20(12):3319-3327.
137. Saridaki Z., Weidhaas J. B., Lenz H. J., Laurent-Puig P., Jacobs B., De Schutter J., De Roock W., Salzman D. W., Zhang W., Yang D., Pilati C., Bouche O., Piessevaux H., et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014; 20(17):4499-4510.
138. Chen X., Guo X., Zhang H., Xiang Y., Chen J., Yin Y., Cai X., Wang K., Wang G., Ba Y., Zhu L., Wang J., Yang R., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28(10):1385-1392.
139. Tsang W. P. and Kwok T. T. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009; 30(6):953-959.
140. Hiraki M., Nishimura J., Takahashi H., Wu X., Takahashi Y., Miyo M., Nishida N., Uemura M., Hata T., Takemasa I., Mizushima T., Soh J. W., Doki Y., et al. Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. Mol Ther Nucleic Acids. 2015; 4:e231.
141. Dong Y., Zhao J., Wu C. W., Zhang L., Liu X., Kang W., Leung W. W., Zhang N., Chan F. K., Sung J. J., Ng S. S. and Yu J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013; 11(9):1051-1060.
142. Danielsen S. A., Eide P. W., Nesbakken A., Guren T., Leithe E. and Lothe R. A. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015; 1855(1):104-121.
143. Arcaroli J. J., Quackenbush . S., Powell R. W., Pitts T. M., Spreafico A., Varella-Garcia M., Bemis L., Tan A. C., Reinemann J. M., Touban B. M., Dasari A., Eckhardt S. G. and Messersmith W. A. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res. 2012; 18(9):2704-2714.
144. Reddy S. M., Kopetz S., Morris J., Parikh N., Qiao W., Overman M. J., Fogelman D., Shureiqi I., Jacobs C., Malik Z., Jimenez C. A., Wolff R. A., Abbruzzese J. L., et al. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015; 33(4):977-984.
145. Guo C., Sah J. F., Beard L., Willson . K., Markowitz S. D. and Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008; 47(11):939-946.
146. Zhong M., Bian Z. and Wu Z. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem. 2013; 31(2-3):209-218.
147. Bonneau D. and Longy M. Mutations of the human PTEN gene. Hum Mutat. 2000; 16(2):109-122.
148. Goel A., Arnold C. N., Niedzwiecki D., Carethers J. M., Dowell J. M., Wasserman L., Compton C., Mayer R. J., Bertagnolli M. M. and Boland C. R. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004; 64(9):3014-3021.
149. Humphreys K. J., Cobiac L., Le Leu R. K., Van Der Hoek M. B. and Michael M. Z. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog. 2013; 52(6):459-474.
150. Iliopoulos D., Jaeger S. A., Hirsch H. A., Bulyk M. L. and Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010; 39(4):493-506.
151. Wu W., Yang J., Feng X., Wang H., Ye S., Yang P., Tan W., Wei G. and Zhou Y. MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer. 2013; 12:30.
152. Ragusa M., Statello L., Maugeri M., Majorana A., Barbagallo D., Salito L., Sammito M., Santonocito M., Angelica R., Cavallaro A., Scalia M., Caltabiano R., Privitera G., et al. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol Med (Berl). 2012; 90(12):1421-1438.
153. Bieging K. T., Mello S. S. and Attardi L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 14(5):359-370.
154. Hollstein M., Sidransky D., Vogelstein B. and Harris C. C. p53 mutations in human cancers. Science. 1991; 253(5015):49-53.
155. Xi Y., Shalgi R., Fodstad O., Pilpel Y. and Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res. 2006; 12(7 Pt 1):2014-2024.
156. He L., He X., Lim L. P., De Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A. L., Linsley P. S., Chen C., et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-1134.
157. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G. and Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007; 6(13):1586-1593.
158. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y. and Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008; 68(11):4123-4132.
159. Akao Y., Noguchi S., Iio A., Kojima K., Takagi T. and Naoe . Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011; 300(2):197-204.
160. Yamakuchi M., Ferlito M. and Lowenstein C. J. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008; 105(36):13421-13426.
161. Braun C. J., Zhang X., Savelyeva I., Wolff S., Moll U. M., Schepeler T., Orntoft T. F., Andersen C. L. and Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008; 68(24):10094-10104.
162. Nishida N., Yokobori T., Mimori K., Sudo T., Tanaka F., Shibata K., Ishii H., Doki Y., Kuwano H. and Mori M. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol. 2011; 38(5):1437-1443.
163. Zhang C., Liu J., Wang X., Wu R., Lin M., Laddha S. V., Yang Q., Chan C. S. and Feng Z. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget. 2014; 5(19):9106-9117. doi: 10.18632/oncotarget.2379.
164. Jones M. and Lal A. MicroRNAs, wild-type and mutant p53: more questions than answers. RNA Biol. 2012; 9(6):781-791.
165. Moustakas A. and Heldin C. H. The regulation of TGFbeta signal transduction. Development. 2009; 136(22):3699-3714.
166. Biswas S., Trobridge P., Romero-Gallo J., Billheimer D., Myeroff L. L., Willson J. K., Markowitz S. D. and Grady W. M. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer. 2008; 47(2):95-106.
167. Bellam N. and Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010; 155:85-103.
168. Yu Y., Kanwar S. S., Patel B. B., Oh P. S., Nautiyal J., Sarkar F. H. and Majumdar A. P. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis. 2012; 33(1):68-76.
169. Feng B., Dong T. T., Wang L. L., Zhou H. M., Zhao H. C., Dong F. and Zheng M. H. Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One. 2012; 7(8):e43452.
170. Liu L., Nie J., Chen L., Dong G., Du X., Wu X., Tang Y. and Han W. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One. 2013; 8(2):e55532.
171. Zhang J., Lu Y., Yue X., Li H., Luo X., Wang Y., Wang K. and Wan J. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One. 2013; 8(8):e70300.
172. Liu M., Bi F., Zhou X. and Zheng Y. Rho GTPase regulation by miRNAs and covalent modifications. Trends Cell Biol. 2012; 22(7):365-373.
173. Liu M., Lang N., Chen X., Tang Q., Liu S., Huang J., Zheng Y. and Bi F. miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett. 2011; 301(2):151-160.
174. Liu M., Lang N., Qiu M., Xu F., Li Q., Tang Q., Chen J., Chen X., Zhang S., Liu Z., Zhou J., Zhu Y., Deng Y., et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011; 128(6):1269-1279.
175. Hansen T. F., Andersen C. L., Nielsen B. S., Spindler K. L., Sorensen F. B., Lindebjerg J., Brandslund I. and Jakobsen A. Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett. 2011; 2(6):1101-1106.
176. Ruzzo A., Graziano F., Vincenzi B., Canestrari E., Perrone G., Galluccio N., Catalano V., Loupakis F., Rabitti C., Santini D., Tonini G., Fiorentini G., Rossi D., et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist. 2012; 17(6):823-829.
177. Igarashi H., Kurihara H., Mitsuhashi K., Ito M., Okuda H., Kanno S., Naito T., Yoshii S., Takahashi H., Kusumi T., Hasegawa T., Sukawa Y., Adachi Y., et al. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Ann Surg Oncol. 2014; 22(8):2640-2648.
178. Svoboda M., Izakovicova Holla L., Sefr R., Vrtkova I., Kocakova I., Tichy B. and Dvorak J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol. 2008; 33(3):541-547.
179. Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H. A., Kitz J., Kaulfuss S., Beissbarth T., Dobbelstein M., Ghadimi M., Grade M. and Gaedcke J. Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol. 2013; 108(3):451-457.
180. Kheirelseid E. A., Miller N., Chang K. H., Curran C., Hennessey E., Sheehan M., Newell J., Lemetre C., Balls G. and Kerin M. J. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis. 2013; 28(2):247-260.
181. Fang L., Li H., Wang L., Hu J., Jin T., Wang J. and Yang B. B. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014; 5(10):2974-2987. doi: 10.18632/oncotarget.1614.
182. Liu K., Li G., Fan C., Zhou X., Wu B. and Li J. Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer. J Int Med Res. 2011; 39(6):2288-2295.
183. Oue N., Anami K., Schetter A. J., Moehler M., Okayama H., Khan M. A., Bowman E. D., Mueller A., Schad A., Shimomura M., Hinoi T., Aoyagi K., Sasaki H., et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer. 2014; 134(8):1926-1934.
184. Molina-Pinelo S., Carnero A., Rivera F., Estevez-Garcia P., Bozada J. M., Limon M. L., Benavent M., Gomez J., Pastor M. D., Chaves M., Suarez R., Paz-Ares L., De La Portilla F., et al. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014; 14:656.
185. Della Vittoria Scarpati G., Falcetta F., Carlomagno C., Ubezio P., Marchini S., De Stefano A., Singh V. K., D'incalci M., De Placido S. and Pepe S. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012; 83(4):1113-1119.
186. Hansen T. F., Nielsen B. S., Sorensen F. B., Johnsson A. and Jakobsen A. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther. 2014; 13(9):2238-2245.
187. Qian X., Yu J., Yin Y., He J., Wang L., Li Q., Zhang L. Q., Li C. Y., Shi Z. M., Xu Q., Li W., Lai L. H., Liu L. Z., et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013; 12(9):1385-1394.
188. Takahashi M., Cuatrecasas M., Balaguer F., Hur K., Toiyama Y., Castells A., Boland C. R. and Goel A. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 2012; 7(10):e46684.
189. Song Y., Xu Y., Wang Z., Chen Y., Yue Z., Gao P., Xing C. and Xu H. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2012; 131(5):1042-1051.
190. Dou R., Deng Y., Huang L., Fu S., Tan S., Wang L., Lian L., Fang L., Fan X., Jin G., Liu H. and Wang J. Multi-microarray identifies lower AQP9 expression in adjuvant chemotherapy nonresponders with stage III colorectal cancer. Cancer Lett. 2013; 336(1):106-113.
191. Bhangu A., Wood G., Brown G., Darzi A., Tekkis P. and Goldin R. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. Colorectal Dis. 2014; 16(4):O133-143.
192. Chen D. L., Wang Z. Q., Zeng Z. L., Wu W. J., Zhang D. S., Luo H. Y., Wang F., Qiu M. Z., Wang D. S., Ren C., Wang F. H., Chiao L. J., Pelicano H., et al. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014; 60(2):598-609.
193. Song B., Wang Y., Titmus M. A., Botchkina G., Formentini A., Kornmann M. and Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010; 9:96.
194. Svoboda M., Sana J., Fabian P., Kocakova I., Gombosova J., Nekvindova J., Radova L., Vyzula R. and Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol. 2012; 7:195.
195. Wan L. Y., Deng J., Xiang X. J., Zhang L., Yu F., Chen J., Sun Z., Feng M. and Xiong J. P. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015; 457(2):125-132.
196. Bitarte N., Bandres E., Boni V., Zarate R., Rodriguez J., Gonzalez-Huarriz M., Lopez I., Javier Sola J., Alonso M. M., Fortes P. and Garcia-Foncillas J. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011; 29(11):1661-1671.
197. Rasmussen M. H., Jensen N. F., Tarpgaard L. S., Qvortrup C., Romer M. U., Stenvang J., Hansen T. P., Christensen L. L., Lindebjerg J., Hansen F., Jensen B. V., Hansen T. F., Pfeiffer P., et al. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 2013; 7(3):637-646.
198. Fassan M., Pizzi M., Giacomelli L., Mescoli C., Ludwig K., Pucciarelli S. and Rugge M. PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch. 2011; 458(4):413-419.
199. Yamamichi N., Shimomura R., Inada K., Sakurai K., Haraguchi T., Ozaki Y., Fujita S., Mizutani T., Furukawa C., Fujishiro M., Ichinose M., Shiogama K., Tsutsumi Y., et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res. 2009; 15(12):4009-4016.
200. Mori Y., Olaru A. V., Cheng Y., Agarwal R., Yang J., Luvsanjav D., Yu W., Selaru F. M., Hutfless S., Lazarev M., Kwon J. H., Brant S. R., Marohn M. R., et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer. 2011; 18(4):465-478.
201. Yang Y., Peng W., Tang T., Xia L., Wang X. D., Duan B. F. and Shu Y. MicroRNAs as promising biomarkers for tumor-staging: evaluation of MiR21 MiR155 MiR29a and MiR92a in predicting tumor stage of rectal cancer. Asian Pac J Cancer Prev. 2014; 15(13):5175-5180.
202. Wang Z. H., Ren L. L., Zheng P., Zheng H. M., Yu Y. N., Wang J. L., Lin Y. W., Chen Y. X., Ge Z. Z., Chen X. Y., Hong J. and Fang J. Y. miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prev Res (Phila). 2014; 7(6):607-616.
203. Peng J., Xie Z., Cheng L., Zhang Y., Chen J., Yu H., Li Z. and Kang H. Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer. BMC Cancer. 2015; 15(1):158.
204. Hansen T. F., Kjaer-Frifeldt S., Christensen R. D., Morgenthaler S., Blondal T., Lindebjerg J., Sorensen F. B. and Jakobsen A. Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer. 2014; 111(7):1285-1292.
205. Schetter A. J., Leung S. Y., Sohn J. J., Zanetti K. A., Bowman E. D., Yanaihara N., Yuen S. T., Chan T. L., Kwong D. L., Au G. K., Liu C. G., Calin G. A., Croce C. M., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-436.
206. Schetter A. J., Nguyen G. H., Bowman E. D., Mathe E. A., Yuen S. T., Hawkes J. E., Croce C. M., Leung S. Y. and Harris C. C. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res. 2009; 15(18):5878-5887.
207. Xia X., Yang B., Zhai X., Liu X., Shen K., Wu Z. and Cai J. Prognostic role of microRNA-21 in colorectal cancer: a meta-analysis. PLoS One. 2013; 8(11):e80426.
208. Zhang H., Li P., Ju H., Pesta M., Kulda V., Jin W., Cai M., Liu C., Wu H., Xu J., Ye Y., Zhang G., Xu E., et al. Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(12):2783-2792.
209. Shibuya H., Iinuma H., Shimada R., Horiuchi A. and Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010; 79(3-4):313-320.
210. Wang F., Zhang P., Ma Y., Yang J., Moyer M. P., Shi C., Peng J. and Qin H. NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA. Cancer Lett. 2012; 314(2):223-231.
211. Han H. B., Gu J., Zuo H. J., Chen Z. G., Zhao W., Li M., Ji D. B., Lu Y. Y. and Zhang Z. Q. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol. 2012; 226(3):544-555.
212. Rohr C., Kerick M., Fischer A., Kuhn A., Kashofer K., Timmermann B., Daskalaki A., Meinel T., Drichel D., Borno S. T., Nowka A., Krobitsch S., Mchardy A. C., et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One. 2013; 8(7):e67461.
213. Strillacci A., Valerii M. C., Sansone P., Caggiano C., Sgromo A., Vittori L., Fiorentino M., Poggioli G., Rizzello F., Campieri M. and Spisni E. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol. 2013; 229(3):379-389.
214. Ak S., Tunca B., Tezcan G., Cecener G., Egeli U., Yilmazlar T., Ozturk E. and Yerci O. MicroRNA expression patterns of tumors in early-onset colorectal cancer patients. J Surg Res. 2014; 191(1):113-122.
215. Hansen T. F., Kjaer-Frifeldt S., Morgenthaler S., Blondal T., Lindebjerg J., Jakobsen A. and Sorensen F. B. The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med. 2014; 12:254.
216. Colangelo T., Fucci A., Votino C., Sabatino L., Pancione M., Laudanna C., Binaschi M., Bigioni M., Maggi C. A., Parente D., Forte N. and Colantuoni V. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013; 15(10):1218-1231.
217. Liu X., Duan B., Dong Y., He C., Zhou H., Sheng H., Gao H. and Zhang X. MicroRNA-139-3p indicates a poor prognosis of colon cancer. Int J Clin Exp Pathol. 2014; 7(11):8046-8052.
218. Chang K. H., Miller N., Kheirelseid E. A., Lemetre C., Ball G. R., Smith M. J., Regan M., Mcanena O. J. and Kerin M. J. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 2011; 26(11):1415-1422.
219. Chen Y., Song Y., Wang Z., Yue Z., Xu H., Xing C. and Liu Z. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010; 14(7):1170-1179.
220. Xiao G., Tang H., Wei W., Li J., Ji L. and Ge J. Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer. Gastroenterol Res Pract. 2014; 2014:364549.
221. Aslam M. I., Venkatesh J., Jameson J. S., West K., Pringle J. H. and Singh B. MicroRNA expression profiling based identification of high risk Dukes' Stage B colorectal cancer: a preliminary study. Colorectal Dis. 2014.
222. Yu G., Tang J. Q., Tian M. L., Li H., Wang X., Wu T., Zhu J., Huang S. J. and Wan Y. L. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J Surg Oncol. 2012; 106(3):232-237.
223. Zhou T., Zhang G. J., Zhou H., Xiao H. X. and Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2014; 26(2):229-233.
224. Wang X., Wang J., Ma H., Zhang J. and Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012; 29(2):919-927.
225. Piepoli A., Tavano F., Copetti M., Mazza T., Palumbo O., Panza A., Di Mola F. F., Pazienza V., Mazzoccoli G., Biscaglia G., Gentile A., Mastrodonato N., Carella M., et al. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 2012; 7(3):e33663.
226. Ge J., Chen Z., Li R., Lu T. and Xiao G. Upregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. Cancer Cell Int. 2014; 14(1):128.
227. Mariani M., He S., Mchugh M., Andreoli M., Pandya D., Sieber S., Wu Z., Fiedler P., Shahabi S. and Ferlini C. Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer. PLoS One. 2014; 9(7):e101065.
228. Karaayvaz M., Pal T., Song B., Zhang C., Georgakopoulos P., Mehmood S., Burke S., Shroyer K. and Ju J. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer. 2011; 10(4):340-347.
229. Liao W. T., Li T. T., Wang Z. G., Wang S. Y., He M. R., Ye Y. P., Qi L., Cui Y. M., Wu P., Jiao H. L., Zhang C., Xie Y. J., Wang J. X., et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013; 19(17):4662-4672.
230. Sun K., Su G., Deng H., Dong J., Lei S. and Li G. Relationship between miRNA-338-3p expression and progression and prognosis of human colorectal carcinoma. Chin Med J (Engl). 2014; 127(10):1884-1890.
231. Takeyama H., Yamamoto H., Yamashita S., Wu X., Takahashi H., Nishimura J., Haraguchi N., Miyake Y., Suzuki R., Murata K., Ohue M., Kato T., Takemasa I., et al. Decreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancer. Mol Cancer Ther. 2014; 13(4):976-985.
232. Dai X., Chiang Y., Wang Z., Song Y., Lu C., Gao P. and Xu H. Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Rep. 2012; 5(5):1299-1304.
233. Li J., Du L., Yang Y., Wang C., Liu H., Wang L., Zhang X., Li W., Zheng G. and Dong Z. MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. Cancer Lett. 2013; 329(1):84-90.
234. Bullock M. D., Pickard K. M., Nielsen B. S., Sayan A. E., Jenei V., Mellone M., Mitter R., Primrose J. N., Thomas G. J., Packham G. K. and Mirnezami A. H. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis. 2013; 4:e684.
235. Drusco A., Nuovo G. J., Zanesi N., Di Leva G., Pichiorri F., Volinia S., Fernandez C., Antenucci A., Costinean S., Bottoni A., Rosito I. A., Liu C. G., Burch A., et al. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One. 2014; 9(6):e96670.
236. Goossens-Beumer I. J., Derr R. S., Buermans H. P., Goeman J. J., Bohringer S., Morreau H., Nitsche U., Janssen K. P., Van De Velde C. J. and Kuppen P. J. MicroRNA classifier and nomogram for metastasis prediction in colon cancer. Cancer Epidemiol Biomarkers Prev. 2015; 24(1):187-197.
237. Bao Y., Chen Z., Guo Y., Feng Y., Li Z., Han W., Wang J., Zhao W., Jiao Y., Li K., Wang Q., Wang J., Zhang H., et al. Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One. 2014; 9(8):e105991.
238. Iino I., Kikuchi H., Miyazaki S., Hiramatsu Y., Ohta M., Kamiya K., Kusama Y., Baba S., Setou M. and Konno H. Effect of miR-122 and its target gene cationic amino acid transporter 1 on colorectal liver metastasis. Cancer Sci. 2013; 104(5):624-630.
239. Wang L. L., Du L. T., Li J., Liu Y. M., Qu A. L., Yang Y. M., Zhang X., Zheng G. X. and Wang C. X. Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2014; 20(32):11340-11346.
240. Duan F. T., Qian F., Fang K., Lin K. Y., Wang W. T. and Chen Y. Q. miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Mol Cancer. 2013; 12:164.
241. Lin C. W., Li X. R., Zhang Y., Hu G., Guo Y. H., Zhou J. Y., Du J., Lv L., Gao K., Zhang Y. and Deng H. TAp63 suppress metastasis via miR-133b in colon cancer cells. Br J Cancer. 2014; 110(9):2310-2320.
242. Zhang Z., Liu X., Feng B., Liu N., Wu Q., Han Y., Nie Y., Wu K., Shi Y. and Fan D. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene. 2015; 34:4808-20.
243. Akcakaya P., Ekelund S., Kolosenko I., Caramuta S., Ozata D. M., Xie H., Lindforss U., Olivecrona H. and Lui W. O. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 2011; 39(2):311-318.
244. Zhang P., Ji D. B., Han H. B., Shi Y. F., Du C. Z. and Gu J. Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroenterol. 2014; 20(34):12241-12248.
245. Hu Y., Liu J., Jiang B., Chen J., Fu Z., Bai F., Jiang J. and Tang Z. MiR-199a-5p loss up-regulated DDR1 aggravated colorectal cancer by activating epithelial-to-mesenchymal transition related signaling. Dig Dis Sci. 2014; 59(9):2163-2172.
246. Qu A., Du L., Yang Y., Liu H., Li J., Wang L., Liu Y., Dong Z., Zhang X., Jiang X., Wang H., Li Z., Zheng G., et al. Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One. 2014; 9(3):e90952.
247. Ellermeier C., Vang S., Cleveland K., Durand W., Resnick M. B. and Brodsky A. S. Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. Anticancer Res. 2014; 34(8):3957-3967.
248. Ke T. W., Hsu H. L., Wu Y. H., Chen W. T., Cheng Y. W. and Cheng C. W. MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis Markers. 2014; 2014:617150.
249. Yuan K., Xie K., Fox J., Zeng H., Gao H., Huang C. and Wu M. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 2013; 145(4):853-864 e859.
250. Lou X., Qi X., Zhang Y., Long H. and Yang J. Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. J Surg Oncol. 2013; 108(4):230-235.
251. Kang W. K., Lee J. K., Oh S. T., Lee S. H. and Jung C. K. Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterol. 2015; 15:2.
252. Li S., Gao J., Gu J., Yuan J., Hua D. and Shen L. MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery. Med Oncol. 2013; 30(2):549.
253. Hansen T. F., Christensen Rd, Andersen . F., Sorensen F. B., Johnsson A. and Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer. 2013; 109(5):1243-1251.
254. Schou J. V., Rossi S., Jensen . V., Nielsen D. L., Pfeiffer P., Hogdall E., Yilmaz M., Tejpar S., Delorenzi M., Kruhoffer M. and Johansen J. S. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS One. 2014; 9(6):e99886.
255. Chen Q., Xia H. W., Ge X. J., Zhang Y. C., Tang Q. L. and Bi F. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev. 2013; 14(12):7421-7426.
256. Hansen T. F., Carlsen A. L., Heegaard N. H., Sorensen F. B. and Jakobsen A. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015; 112(4):624-629.
257. Chen J., Wang W., Zhang Y., Chen Y. and Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol. 2014; 31(1):799.
258. Faltejskova P., Bocanek O., Sachlova M., Svoboda M., Kiss I., Vyzula R. and Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012; 12(4):199-204.
259. Giraldez M. D., Lozano J. J., Ramirez G., Hijona E., Bujanda L., Castells A. and Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013; 11(6):681-688 e683.
260. Zheng G., Du L., Yang X., Zhang X., Wang L., Yang Y., Li J. and Wang C. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br J Cancer. 2014; 111(10):1985-1992.
261. Toiyama Y., Takahashi M., Hur K., Nagasaka T., Tanaka K., Inoue Y., Kusunoki M., Boland C. R. and Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013; 105(12):849-859.
262. Basati G., Emami Razavi A., Abdi S. and Mirzaei A. Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Med Oncol. 2014; 31(10):205.
263. Wang B. and Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012; 138(10):1659-1666.
264. Wang J., Huang S. K., Zhao M., Yang M., Zhong J. L., Gu Y. Y., Peng H., Che Y. Q. and Huang C. Z. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014; 9(4):e87451.
265. Zanutto S., Pizzamiglio S., Ghilotti M., Bertan C., Ravagnani F., Perrone F., Leo E., Pilotti S., Verderio P., Gariboldi M. and Pierotti M. A. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J Cancer. 2014; 110(4):1001-1007.
266. Du M., Liu S., Gu D., Wang Q., Zhu L., Kang M., Shi D., Chu H., Tong N., Chen J., Adams T. S., Zhang Z. and Wang M. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis. 2014; 35(12):2723-2730.
267. Huang Z., Huang D., Ni S., Peng Z., Sheng W. and Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127(1):118-126.
268. Nugent M., Miller N. and Kerin M. J. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012; 106(8):947-952.
269. Yin Y., Yan Z. P., Lu N. N., Xu Q., He J., Qian X., Yu J., Guan X., Jiang B. H. and Liu L. Z. Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim Biophys Acta. 2013; 1829(2):239-247.
270. Ramzy I., Hasaballah M., Marzaban R., Shaker O. and Soliman Z. A. Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study. Clin Res Hepatol Gastroenterol. 2015.
271. Yong F. L., Law C. W. and Wang C. W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013; 13:280.
272. Xu L., Li M., Wang M., Yan D., Feng G. and An G. The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer. 2014; 14:714-725.
273. Wang S., Xiang J., Li Z., Lu S., Hu J., Gao X., Yu L., Wang L., Wang J., Wu Y., Chen Z. and Zhu H. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015; 136(1):152-161.
274. Hofsli E., Sjursen W., Prestvik W. S., Johansen J., Rye M., Trano G., Wasmuth H. H., Hatlevoll I. and Thommesen L. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013; 108(8):1712-1719.
275. Lu X. and Lu J. The significance of detection of serum miR-423-5p and miR-484 for diagnosis of colorectal cancer. Clin Lab. 2015; 61(1-2):187-190.
276. Kanaan Z., Roberts H., Eichenberger M. R., Billeter A., Ocheretner G., Pan J., Rai S. N., Jorden J., Williford A. and Galandiuk S. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013; 258(3):400-408.
277. Wang Q., Huang Z., Ni S., Xiao X., Xu Q., Wang L., Huang D., Tan C., Sheng W. and Du X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398.
278. Ahmed F. E., Amed N. C., Vos P. W., Bonnerup C., Atkins J. N., Casey M., Nuovo G. J., Naziri W., Wiley J. E. and Allison R. R. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics. 2012; 9(4):179-192.
279. Menendez P., Padilla D., Villarejo P., Palomino T., Nieto P., Menendez J. M. and Rodriguez-Montes J. A. Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol. 2013; 108(6):369-373.
280. Jinushi T., Shibayama Y., Kinoshita I., Oizumi S., Jinushi M., Aota T., Takahashi T., Horita S., Dosaka-Akita H. and Iseki K. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014; 3(6):1544-1552.
281. Cheng H., Zhang L., Cogdell D. E., Zheng H., Schetter A. J., Nykter M., Harris C. C., Chen K., Hamilton S. R. and Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6(3):e17745.
282. Lv Z. C., Fan Y. S., Chen H. B. and Zhao D. W. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol. 2015; 36(3):1619-1625.
283. Toiyama Y., Hur K., Tanaka K., Inoue Y., Kusunoki M., Boland C. R. and Goel A. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014; 259(4):735-743.
284. Yu H., Gao G., Jiang L., Guo L., Lin M., Jiao X., Jia W. and Huang J. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2013; 6(12):2904-2911.
285. Yong F. L., Wang C. W., Roslani A. C. and Law C. W. The involvement of miR-23a/APAF1 regulation axis in colorectal cancer. Int J Mol Sci. 2014; 15(7):11713-11729.
286. Wang L. G. and Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012; 36(1):e61-67.
287. Yamada N., Nakagawa Y., Tsujimura N., Kumazaki M., Noguchi S., Mori T., Hirata I., Maruo K. and Akao Y. Role of Intracellular and Extracellular MicroRNA-92a in Colorectal Cancer. Transl Oncol. 2013; 6(4):482-492.
288. Hur K., Toiyama Y., Schetter A. J., Okugawa Y., Harris C. C., Boland C. R. and Goel A. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst. 2015; 107(3).
289. Yin J., Bai Z., Song J., Yang Y., Wang J., Han W., Zhang J., Meng H., Ma X., Yang Y., Wang T., Li W. and Zhang Z. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res. 2014; 26(1):95-103.
290. Shivapurkar N., Weiner L. M., Marshall J. L., Madhavan S., Deslattes Mays A., Juhl H. and Wellstein A. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One. 2014; 9(1):e84686.
291. Brunet Vega A., Pericay C., Moya I., Ferrer A., Dotor E., Pisa A., Casalots A., Serra-Aracil X., Oliva J. C., Ruiz A. and Saigi E. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013; 30(1):320-326.
292. Yang I. P., Tsai H. L., Huang C. W., Huang M. Y., Hou M. F., Juo S. H. and Wang J. Y. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One. 2013; 8(6):e66842.
293. Tsai H. L., Yang I. P., Huang C. W., Ma C. J., Kuo C. H., Lu C. Y., Juo S. H. and Wang J. Y. Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection. Transl Res. 2013; 162(4):258-268.
294. Ahmed F. E., Ahmed N. C., Vos P. W., Bonnerup C., Atkins J. N., Casey M., Nuovo G. J., Naziri W., Wiley J. E., Mota H. and Allison R. R. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics. 2013; 10(3):93-113.
295. Link A., Balaguer F., Shen Y., Nagasaka T., Lozano J. J., Boland C. R. and Goel A. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010; 19(7):1766-1774.
296. Wu X. D., Song Y. C., Cao P. L., Zhang H., Guo Q., Yan R., Diao D. M., Cheng Y. and Dang C. X. Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. Med Oncol. 2014; 31(4):894.
297. Kalimutho M., Di Cecilia S., Del Vecchio Blanco G., Roviello F., Sileri P., Cretella M., Formosa A., Corso G., Marrelli D., Pallone F., Federici G. and Bernardini S. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer. 2011; 104(11):1770-1778.
298. Wu C. W., Ng S. C., Dong Y., Tian L., Ng S. S., Leung W. W., Law W. T., Yau T. O., Chan F. K., Sung J. J. and Yu J. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. 2014; 20(11):2994-3002.
299. Li J. M., Zhao R. H., Li S. T., Xie C. X., Jiang H. H., Ding W. J., Du P., Chen W., Yang M. and Cui L. Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med J. 2012; 33(1):24-29.
300. Kalimutho M., Del Vecchio Blanco G., Di Cecilia S., Sileri P., Cretella M., Pallone F., Federici G. and Bernardini S. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011; 46(12):1391-1402.
301. Yau T. O., Wu C. W., Dong Y., Tang C. M., Ng S. S., Chan F. K., Sung J. J. and Yu J. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 2014; 111(9):1765-1771.
302. Phua L. C., Chue X. P., Koh P. K., Cheah P. Y., Chan E. C. and Ho H. K. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncol Rep. 2014; 32(1):97-104.
303. Link A., Balaguer F., Nagasaka T., Boland C. R. and Goel A. MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract. PLoS One. 2014; 9(6):e100036.
304. Wu C. W., Ng S. S., Dong Y. J., Ng S. C., Leung W. W., Lee C. W., Wong Y. N., Chan F. K., Yu J. and Sung J. J. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012; 61(5):739-745.
305. Rotelli M. T., Di Lena M., Cavallini A., Lippolis C., Bonfrate L., Chetta N., Portincasa P. and Altomare D. F. Fecal microRNA profile in patients with colorectal carcinoma before and after curative surgery. Int J Colorectal Dis. 2015; 30(7):891-898.